More than 130 suppliers

In-house tech support

Call +31 (0)26 326 44 50

Bio-Connect

Products
Products
Antibodies
Chemicals
Proteins / Signaling Molecules
Assays
DNA / RNA / Vectors
Cell Culture
Genome Editing and Engineering
Molecular Biology
Lysates / Extracts
Expression
Labware / Accesories
Body Products
Technique Specific Products
Arrays / Slides
All product groups
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Research
Research
Cancer research
Epigenetics research
Immunology and inflammation research
Neuroscience research
Virology research
SARS-CoV-2
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
Industries
Suppliers

Tech support
News
About us
About us
Our company
Our people
Divisions
Vacatures
Events
Promotions
Support your research
For 15 years, we connect life science researchers specialized in the import and distribution of life science reagents from global suppliers.
How can we help?
FAQ
Contact

ProductsBack/Afatinib [850140-72-6; 439081-18-2]

Afatinib [850140-72-6; 439081-18-2]

A2077

Estimated Purity≥98%

DownloadDatasheet

Product group Chemicals

Overview

Supplier
LKT Laboratories
Product Name
Afatinib [850140-72-6; 439081-18-2]
Delivery Days Customer
7
Estimated Purity
≥98%
Scientific Description
EGFR inhibitor.; BIBW 2992
Storage Instruction
4°C
UNSPSC
12352200

References

Yap TA, Popat S. The role of afatinib in the management of non-small cell lung carcinoma. Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1529-39. PMID: 23985030. Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013 Jun;54(6):936-43. PMID: 23578997. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012 Nov;343(2):342-50. PMID: 22888144. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011 Jul;7(7):817-25. PMID: 21732753.